Haarausfall - Allgemeines Forum : Studien Finasterid » Hagberg et al. (2016). Risk of erectile dysfunction associated with use of 5-α reductase...

Haarausfall - Allgemeines Forum :: Haarverlust, Mittel gegen Haarausfall (Finasterid, Minoxidil), Haarersatz

Startseite » Forschung » Studien Finasterid » Hagberg et al. (2016). Risk of erectile dysfunction associated with use of 5-α reductase... (...inhibitors for benign prostatic hyperplasia or alopecia)

Anzeigen: Heutige Beiträge :: Umfragen :: Beitragsnavigator
E-Mail an einen Freund

Zur flachen Standardansicht zurückkehren

vmPFC Hagberg et al. (2016). Risk of erectile dysfunction associated with use of 5-α reductase... [Beitrag #375042] :: Mi., 19 Oktober 2016 19:51
vmPFC Beiträge: 541 Registriert: April 2015 Reputation: Power Member *	Link: http://www.bmj.com/content/bmj/354/bmj.i4823.full.pdf Abstract Objective: To estimate the risk of erectile dysfunction in men who used 5-α reductase inhibitors to treat benign prostatic hyperplasia or alopecia. Design: Cohort studies with nested case-control analyses. Setting: UK Clinical Practice Research Datalink. Population: Two populations of men free of risk factors for erectile dysfunction and other sexual dysfunction or its treatment: men aged 40 or more with benign prostatic hyperplasia who received a prescription for a 5-α reductase inhibitor (finasteride or dutasteride) or α blocker, or both, and men aged 18-59 with alopecia. Exposures: In the benign prostatic hyperplasia study, exposures were classified as 5-α reductase inhibitors only, 5-α reductase inhibitors+α blockers, or α blockers only. In the alopecia study, exposures were finasteride 1 mg or no treatment. Main outcome measures: Cases were men with a diagnosis of erectile dysfunction or treatment (procedure or prescription for a phosphodiesterase type 5 inhibitor) during follow-up. We calculated incidence rates and adjusted incidence rate ratios with 95% confidence intervals. We also conducted nested case-control analyses to control for major confounders, and calculated adjusted odds ratios with 95% confidence intervals. Results: In the population with benign prostatic hyperplasia (n=71 849), the risk of erectile dysfunction was not increased with use of 5-α reductase inhibitors only (incidence rate ratio 0.92, 95% confidence interval 0.85 to 0.99; odds ratio 0.94, 95% confidence interval 0.85 to 1.03) or 5-α reductase inhibitors+α blocker (1.09, 0.99 to 1.21, 0.92; 0.80 to 1.06) compared with α blockers only, and remained null regardless of number of prescriptions or timing of use. The risk of erectile dysfunction increased with longer duration of benign prostatic hyperplasia, regardless of exposure. For the alopecia population (n=12 346), the risk of erectile dysfunction was not increased for users of finasteride 1 mg compared with unexposed men with alopecia (1.03, 0.73 to 1.44; 0.95, 0.64 to 1.41). Conclusion: 5-α reductase inhibitors do not seem to significantly increase the risk of incident erectile dysfunction, regardless of indication for use. Risk of erectile dysfunction increased with longer duration of benign prostatic hyperplasia. [Aktualisiert am: Mi., 19 Oktober 2016 19:54] Fin seit 2009 (1.25mg/Woche); Minox seit 2011; Ket seit 2012 (1%/Tag) Abgesetzt: Dut 2011-2017 (0.05mg/Woche); RU 2014-2017 (3%/Tag)
Den Beitrag einem Moderator melden